• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
news type
Fierce Pharma logo, red copy on white background
In the media
27 Feb 2026

After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review’

Fierce Pharma
Citizen TV logo
In the media
27 Feb 2026

EMA gives positive opinion for single-dose sleeping sickness medication

Citizen Digital
In the media
27 Feb 2026

Single-dose sleeping sickness pill clears major EU regulatory milestone

Capital FM
Acoziborole pill in hand
Press Releases Translations
27 Feb 2026

L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif de l’Agence Européenne des Médicaments (EMA) en tant que traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil

Acoziborole pill in hand
Press releases
27 Feb 2026

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

KBC logo
In the media
27 Feb 2026

Breakthrough single-dose treatment for sleeping sickness gets EU nod

KBC
AP logo
In the media
27 Feb 2026

New sleeping sickness pill gets nod, paving the way for use in Africa

Associated Press
Scientific articles
27 Feb 2026

Evaluation of drug–drug interaction potential between the oral antibiotic zoliflodacin and the CYP3A4 inhibitor itraconazole: A phase 1 study in healthy participants

Clinical and Translational Science
Bloomberg logo
In the media
27 Feb 2026

New pill has potential to eliminate deadly sleeping sickness

Bloomberg
Le Monde logo
In the media
27 Feb 2026

Maladie du sommeil : l’autorisation européenne d’un nouveau traitement laisse entrevoir une élimination de la maladie d’ici à 2030

Le Monde
France 24 logo
In the media
27 Feb 2026

La maladie du sommeil bientôt éliminée ? Feu vert européen à un nouveau traitement

France 24
Science logo
In the media
27 Feb 2026

‘Truly spectacular’ drug for sleeping sickness simplifies treatment, raising hopes for eradication

Science
Scientific articles
26 Feb 2026

A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data

Journal of Chemical Information and Modeling
China Philantrophist magazine logo, cp letters in dark red and chinese characters in black
In the media
26 Feb 2026

被忽视疾病的希望

China Philanthropy Magazine
Scientific articles
24 Feb 2026

Elimination of visceral leishmaniasis as a public health problem in Bangladesh: Lessons learned and questions remaining

PLOS Neglected Tropical Diseases
Scientific articles
24 Feb 2026

Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections and associated risk factors among pregnant women and key populations in Kenya: A multi-centre cross-sectional study

PLOS Global Public Health
Page1 Page2 Page3 Page4 Page5
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license